BioAge Labs (BIOA) Competitors

$19.14 +0.95 (+5.22%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$19.08 -0.06 (-0.33%)

As of 04:13 AM Eastern

BIOA vs. DYN, MOR, TARS, KOD, and IMNM

Should you buy BioAge Labs stock or one of its competitors? MarketBeat compares BioAge Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAge Labs include Dyne Therapeutics (DYN), MorphoSys (MOR), Tarsus Pharmaceuticals (TARS), Kodiak Sciences (KOD), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry.

How does BioAge Labs compare to Dyne Therapeutics?

BioAge Labs (NASDAQ:BIOA) and Dyne Therapeutics (NASDAQ:DYN) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Dyne Therapeutics had 3 more articles in the media than BioAge Labs. MarketBeat recorded 12 mentions for Dyne Therapeutics and 9 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.79 beat Dyne Therapeutics' score of 0.66 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

BioAge Labs has higher revenue and earnings than Dyne Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	94.64	-$80.61M	-$2.40	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioAge Labs currently has a consensus price target of $45.00, suggesting a potential upside of 135.11%. Dyne Therapeutics has a consensus price target of $35.21, suggesting a potential upside of 90.97%. Given BioAge Labs' higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Dyne Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Summary

BioAge Labs and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to MorphoSys?

BioAge Labs (NASDAQ:BIOA) and MorphoSys (NASDAQ:MOR) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

In the previous week, BioAge Labs had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for BioAge Labs and 0 mentions for MorphoSys. BioAge Labs' average media sentiment score of 0.79 beat MorphoSys' score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Overall Sentiment
BioAge Labs	Positive
MorphoSys	Neutral

BioAge Labs has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

BioAge Labs has higher earnings, but lower revenue than MorphoSys. BioAge Labs is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	94.64	-$80.61M	-$2.40	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

18.4% of MorphoSys shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioAge Labs currently has a consensus price target of $45.00, suggesting a potential upside of 135.11%. Given BioAge Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MorphoSys has a net margin of -226.79% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
MorphoSys	-226.79%	-694.31%	-22.55%

Summary

BioAge Labs beats MorphoSys on 10 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Tarsus Pharmaceuticals currently has a consensus price target of $90.67, indicating a potential upside of 40.22%. BioAge Labs has a consensus price target of $45.00, indicating a potential upside of 135.11%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tarsus Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 23 more articles in the media than BioAge Labs. MarketBeat recorded 32 mentions for Tarsus Pharmaceuticals and 9 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.79 beat Tarsus Pharmaceuticals' score of 0.21 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has higher revenue and earnings than BioAge Labs. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.16	-$66.42M	-$1.14	N/A
BioAge Labs	$8.99M	94.64	-$80.61M	-$2.40	N/A

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 20.8% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals has a net margin of -9.02% compared to BioAge Labs' net margin of -871.75%. Tarsus Pharmaceuticals' return on equity of -14.19% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
BioAge Labs	-871.75%	-29.40%	-27.26%

Summary

Tarsus Pharmaceuticals beats BioAge Labs on 10 of the 17 factors compared between the two stocks.

How does BioAge Labs compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Kodiak Sciences currently has a consensus price target of $42.14, indicating a potential upside of 6.39%. BioAge Labs has a consensus price target of $45.00, indicating a potential upside of 135.11%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts plainly believe BioAge Labs is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Kodiak Sciences has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

In the previous week, Kodiak Sciences had 13 more articles in the media than BioAge Labs. MarketBeat recorded 22 mentions for Kodiak Sciences and 9 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.79 beat Kodiak Sciences' score of -0.01 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
BioAge Labs	$8.99M	94.64	-$80.61M	-$2.40	N/A

89.1% of Kodiak Sciences shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by company insiders. Comparatively, 20.8% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kodiak Sciences has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
BioAge Labs	-871.75%	-29.40%	-27.26%

Summary

BioAge Labs beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to Immunome?

Immunome (NASDAQ:IMNM) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Immunome has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-57.71%	-52.69%
BioAge Labs	-871.75%	-29.40%	-27.26%

In the previous week, Immunome had 1 more articles in the media than BioAge Labs. MarketBeat recorded 10 mentions for Immunome and 9 mentions for BioAge Labs. Immunome's average media sentiment score of 1.28 beat BioAge Labs' score of 0.79 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome currently has a consensus price target of $33.45, indicating a potential upside of 50.70%. BioAge Labs has a consensus price target of $45.00, indicating a potential upside of 135.11%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

BioAge Labs has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	362.27	-$212.39M	-$2.42	N/A
BioAge Labs	$8.99M	94.64	-$80.61M	-$2.40	N/A

44.6% of Immunome shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 20.8% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Immunome has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Summary

Immunome beats BioAge Labs on 9 of the 17 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOA vs. The Competition

Export

Metric	BioAge Labs	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$808.59M	$2.96B	$4.27B	$12.20B
Dividend Yield	N/A	15.20%	6.10%	5.30%
P/E Ratio	-7.97	13.21	23.37	25.58
Price / Sales	94.64	1,909.66	157.54	78.84
Price / Cash	N/A	26.94	51.43	55.34
Price / Book	2.24	4.31	37.09	6.66
Net Income	-$80.61M	-$42.51M	$114.78M	$333.63M
7 Day Performance	7.41%	0.48%	1.97%	-0.11%
1 Month Performance	15.51%	2.82%	4.00%	3.94%
1 Year Performance	N/A	18.52%	16.86%	36.07%

BioAge Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOA BioAge Labs	3.0264 of 5 stars	$19.14 +5.2%	$45.00 +135.1%	N/A	$808.59M	$8.99M	N/A	N/A	Earnings Report Analyst Forecast
DYN Dyne Therapeutics	3.3251 of 5 stars	$17.40 +0.1%	$35.14 +101.9%	+52.4%	$2.88B	N/A	N/A	100	Earnings Report Analyst Forecast
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
TARS Tarsus Pharmaceuticals	3.1013 of 5 stars	$63.09 -0.8%	$90.67 +43.7%	+56.0%	$2.72B	$451.36M	N/A	50	Analyst Revision
KOD Kodiak Sciences	1.2088 of 5 stars	$42.98 -2.2%	$35.43 -17.6%	+882.9%	$2.68B	N/A	N/A	90	Trending News Earnings Report Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAge Labs (BIOA) Competitors

BIOA vs. DYN, MOR, TARS, KOD, and IMNM

How does BioAge Labs compare to Dyne Therapeutics?

Summary

How does BioAge Labs compare to MorphoSys?

Summary

How does BioAge Labs compare to Tarsus Pharmaceuticals?

Summary

How does BioAge Labs compare to Kodiak Sciences?

Summary

How does BioAge Labs compare to Immunome?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAge Labs (BIOA) Competitors

BIOA vs. DYN, MOR, TARS, KOD, and IMNM

How does BioAge Labs compare to Dyne Therapeutics?

Does the media refer more to BIOA or DYN?

Which has more volatility and risk, BIOA or DYN?

Which has preferable valuation and earnings, BIOA or DYN?

Do insiders and institutionals hold more shares of BIOA or DYN?

Do analysts prefer BIOA or DYN?

Is BIOA or DYN more profitable?

Summary

How does BioAge Labs compare to MorphoSys?

Does the media refer more to BIOA or MOR?

Which has more volatility and risk, BIOA or MOR?

Which has preferable valuation and earnings, BIOA or MOR?

Do insiders and institutionals hold more shares of BIOA or MOR?

Do analysts prefer BIOA or MOR?

Is BIOA or MOR more profitable?

Summary

How does BioAge Labs compare to Tarsus Pharmaceuticals?

Do analysts rate TARS or BIOA?

Which has more risk and volatility, TARS or BIOA?

Does the media prefer TARS or BIOA?

Which has better valuation & earnings, TARS or BIOA?

Do institutionals and insiders hold more shares of TARS or BIOA?

Is TARS or BIOA more profitable?

Summary

How does BioAge Labs compare to Kodiak Sciences?

Do analysts rate KOD or BIOA?

Which has more risk and volatility, KOD or BIOA?

Does the media prefer KOD or BIOA?

Which has better valuation & earnings, KOD or BIOA?

Do institutionals and insiders hold more shares of KOD or BIOA?

Is KOD or BIOA more profitable?

Summary

How does BioAge Labs compare to Immunome?

Is IMNM or BIOA more profitable?

Does the media prefer IMNM or BIOA?

Do analysts rate IMNM or BIOA?

Which has better valuation & earnings, IMNM or BIOA?

Do institutionals and insiders hold more shares of IMNM or BIOA?

Which has more risk and volatility, IMNM or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools